STOCK TITAN

Akebia Therapeut - AKBA STOCK NEWS

Welcome to our dedicated page for Akebia Therapeut news (Ticker: AKBA), a resource for investors and traders seeking the latest updates and insights on Akebia Therapeut stock.

Akebia Therapeutics, Inc. (AKBA) is a biopharmaceutical leader developing innovative therapies for kidney disease, including FDA-approved Auryxia® and investigational oral HIF inhibitor Vafseo™. This page provides authorized updates on clinical developments, regulatory milestones, and strategic initiatives shaping renal care.

Access Akebia's official press releases covering phase 3 trial results, regulatory submissions, and commercial partnerships with dialysis providers. Investors will find timely updates on financial performance, including earnings calls and SEC filings related to anemia treatment innovations.

Our curated news collection helps stakeholders track progress in HIF biology applications and chronic kidney disease management. Bookmark this page for verified updates on product approvals, research collaborations, and market expansion strategies directly from Akebia Therapeutics.

Rhea-AI Summary
Akebia Therapeutics, Inc. granted its new Senior Vice President, Chief Financial Officer, and Treasurer, Ellen Snow, options to purchase 560,000 shares of the company's common stock at an exercise price of $1.67 per share. The options vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and the remaining 75% vesting quarterly thereafter, subject to Ms. Snow's continued service with Akebia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.98%
Tags
none
-
Rhea-AI Summary
Akebia Therapeutics, Inc. (Nasdaq: AKBA) announced that CEO John Butler will participate in a fireside chat at the H.C. Wainwright 2nd Annual Kidney Conference to discuss recent regulatory updates regarding vadadustat, Akebia's oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of anemia due to chronic kidney disease in adult patients on dialysis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.98%
Tags
conferences
-
Rhea-AI Summary
Akebia Therapeutics announced completion of an End of Dispute Type A meeting with the FDA regarding the resubmission of its NDA for vadadustat as a treatment for anemia due to CKD in adult patients on dialysis. The meeting was productive and Akebia plans to resubmit the NDA by the end of Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.5%
Tags
Rhea-AI Summary
Akebia Therapeutics grants two newly-hired employees options to purchase 24,000 shares of common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.57%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.18%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.8%
Tags
none
Rhea-AI Summary
Akebia Therapeutics announces Ellen Snow as new CFO and Treasurer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.38%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
none
Rhea-AI Summary
FDA denies formal dispute resolution, but outlines path to resubmit NDA for dialysis-dependent patients without new clinical studies. Akebia plans to request Type A meeting and then resubmit NDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.13%
Tags
none
Akebia Therapeut

Nasdaq:AKBA

AKBA Rankings

AKBA Stock Data

538.14M
232.73M
4.45%
28.9%
6.82%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
CAMBRIDGE